Modra’s oral formulation of docetaxel, ModraDoc006/r will bypass limitations associated with IV-delivered docetaxel and at the same time improve the bioavailability of the drug. ModraDoc006/r is currently in a Phase II study in patients with metastatic prostate cancer.
Docetaxel, a member of the taxane class of chemotherapeutics, is one of the most frequently applied anti-cancer drugs globally and is part of the standard treatment practices for several major cancer indications. Although part of docetaxel’s toxicity is related to its mode of action, a substantial level of toxicity is induced by the high initial docetaxel blood concentration after intravenous administration. Its excipients, polysorbate 80 and ethanol, are known to cause side effects. 


Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial
Read more

Modra's Unique Approach

improving patient lives    
Learn more


Meet us at one of the following events:      
Read more